Spero Therapeutics Appoints Thomas Parr, Ph.D. as Chief Scientific Officer

  Spero Therapeutics Appoints Thomas Parr, Ph.D. as Chief Scientific Officer

 -- Company assembles Scientific Advisory Board comprised of world-leaders in
microbiology and the clinical development of anti-infectives to combat severe
  infections resulting from highly drug-resistant, gram-negative bacteria --

Business Wire

CAMBRIDGE, Mass. -- May 20, 2014

Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel
therapies targeting virulence and persistence, for treatment of bacterial
infections, today announced that Thomas “Tom” Parr, Ph.D. has joined the
company as Chief Scientific Officer. Dr. Parr is a highly regarded
microbiologist with more than 25 years of drug discovery experience across
both large pharmaceutical and small biotechnology companies. The company also
announced its Scientific Advisory Board (SAB). This world-renowned group of
scientists brings expertise in key areas that will be invaluable in
transitioning Spero’s portfolio of first-in-class anti-infectives for severe,
drug-resistant infections from discovery into clinical trials.

"Tom is a talented CSO who brings to Spero substantial scientific experience
in anti-infectives from discovery through commercial development," said Ankit
Mahadevia, M.D., Venture Partner at Atlas Venture and Spero’s President. “As
rates of bacterial resistance even to last-line antibiotics continue to rise,
we look forward to Tom’s contributions to our senior management team so we may
aggressively pursue the development of treatments for this evolving public
health emergency.”

"We are very pleased to bring together these key thought leaders to establish
the Spero Scientific Advisory Board," stated Dr. Parr. "Their deep insight in
antimicrobial medicinal chemistry and in vitroandin vivo microbiology will
be instrumental in advancing our therapeutic programs into clinical
development. Further, the interest and direct participation of these
world-class scientists on our SAB reflects the progress we're making in the
discovery of new anti-infective therapies that must overcome existing drug
resistance mechanisms and both limit the damage caused by the infection and
promote its clearance."

Prior to joining Spero, Dr. Parr was the Chief Scientific Officer at Fedora
Pharmaceuticals when the company was directing novel beta-lactamase inhibitors
toward development partnerships. Earlier, he was the Chief Scientific Officer
at Targanta Therapeutics, now part of The Medicines Company. While at
Targanta, Dr. Parr was instrumental in progressing the lipoglycopeptide,
oritavancin through to registration meetings with the FDA and EMA. Dr. Parr
has worked on a broad range of marketed and experimental antibiotics including
beta-lactams (cefaclor, loracarbef, cefuroxime axetil, cephalexin, moxalactam,
ceftazidime, cefazolin, RWJ-333441); glycopeptides (vancomycin and
oritavancin); lipodepsipeptides (daptomycin); aminoglycosides (tobramycin);
quinolones (cinoxacin); macrolides (dirythromycin); and antimicrobial peptides
(iseganins).

Dr. Parr earned his Ph.D. from the University of Calgary and was an MRC
postdoctoral fellow at the University of British Columbia. He was an Assistant
Professor in the Department of Microbiology and Biochemistry at the University
of Ottawa before beginning his drug discovery and development career.

Chaired by Dr. Laurence Rahme, the members of the Spero Scientific Advisory
Board include the following:

  *Laurence Rahme, M.S., Ph.D., is the Spero Scientific Founder and an
    Associate Professor in the Departments of Surgery, Microbiology and
    Immunobiology at Harvard Medical School and Director of the Molecular
    Surgical Laboratory and Associate Microbiologist in the Department of
    Surgery at Massachusetts General Hospital, where she is also affiliated
    with the Departments of Molecular Biology and Division of Infectious
    Diseases. Dr. Rahme is internationally known for pioneering the use of P.
    aeruginosa as a multi-host pathogen, the use of non-vertebrate hosts to
    study P. aeruginosa-host interactions, and the development of
    anti-virulence drugs that block pathogenesis but not cell viability.
  *Paul Ambrose, Pharm. D. President of the Institute for Clinical
    Pharmacodynamics (ICPD), Latham, New York. He is also an Honorary Research
    Fellow in Infectious Diseases at the University of Oxford, Oxford, UK and
    Adjunct Associate Research Professor at the University at Buffalo,
    Buffalo, New York. Dr. Ambrose is an expert in anti-infective
    translational science, with the goal of improving patient care through the
    application of pharmacokinetic-pharmacodynamic (PK-PD) principles.
  *Gordon Archer, M.D. is the Senior Associate Dean for Research and Research
    Training in the Virginia Commonwealth University School of Medicine where
    he directs both the M.D.-Ph.D. combined degree and the Ph.D. pre-doctoral
    programs. Dr. Archer is an expert in the study of staphylococci and,
    specifically antimicrobial resistance in staphylococci with a focus on
    antibiotic resistance gene exchange and plasmid biology.
  *George L. Drusano, M.D. is Professor of Medicine and Director, Institute
    for Therapeutic Innovation of the University of Florida. He has more than
    290 peer-reviewed articles and is a leader in the understanding of
    mathematical modeling and pharmacodynamics for anti-infective
    chemotherapy.
  *Jacques Dumas, Ph.D. Chief Scientific Officer at Idenix (Cambridge,
    Mass.), a public company focused on antiviral therapies, for which he
    oversees all aspects of discovery and non-clinical development.
    Preivously, Jacques was Vice President and Head of Strategy for Infectious
    Diseases at Astrazeneca. Dr. Dumas is a medicinal chemist with expertise
    in infectious disease and oncology. He is co-inventor of Nexavar and
    Stivarga, two approved oncology drugs.
  *Eric Gordon, PhDhas been a distinguished medicinal chemist, company
    founder and senior executive since the early 1970s. He was Director of
    medicinal chemistry at the Squibb Institute for Medical Research and later
    Bristol-Myers Squibb, where he worked for 18 years. Since the early 1990s
    Eric has participated in the building of several successful biotech
    companies including Affymax, Versicor (later Vicuron Pharmaceuticals,
    which was acquired by Pfizer in 2005), and Sunesis Pharmaceuticals.
  *Brad Spellberg, M.D. is Professor of Medicine at the David Geffen School
    of Medicine at UCLA and the Harbor-UCLA Medical Center. He is also the
    Associate Medical Director for Inpatient Services and an Associate Program
    Director for the Internal Medicine Residency Training Program at
    Harbor-UCLA Medical Center. Dr. Spellberg is an expert in immunology,
    vaccinology, and host defense against highly resistant Gram negative
    bacilli, including Acinetobacter and carbapenem-resistant
    Enterobacteriaceae infections.
  *Glenn Tillotson, Ph.D. is a pharmaceutical industry executive with
    extensive experience ranging from clinical research, to commercialization,
    medical affairs, scientific communications including publication planning,
    strategic drug development, life cycle management and global launch
    programs. Dr. Tillotson is an expert in the development of anti-invectives
    including ciprofloxacin, moxifloxacin, gemifloxacin and fidaxomicin.

About Spero

Spero is a product-focused biopharmaceutical company developing novel
treatments for bacterial infections and is located in Cambridge,
Massachusetts. Spero is taking a novel approach that works differently from
existing antibiotics by targeting a pathway involved in two critical bacterial
processes: virulence and persistence. Spero’s drug candidates may uniquely
reduce the morbidity caused by severe infections and promote their clearance,
including in bacterial strains highly resistant to even the most potent
existing antibiotics. For more information, please visit
www.sperotherapeutics.com.

Contact:

Spero Therapeutics
Ankit Mahadevia, M.D.
Venture Partner at Atlas Ventures
or
Suda Communications LLC
Maureen L. Suda (Media), 585-387-9248
 
Press spacebar to pause and continue. Press esc to stop.